Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

 

Lymphoid Malignancies
15:03

Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

State of the Art in the Management of Follicular Lymphoma: Early Stage Disease and the Firstline Therapy

FEATURING Hayder Saeed
  • 50 views
  • January 27, 2020
11:21

Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

State of the Art in the Management of Follicular Lymphoma: Rule of Lenalidomide in Treatment, PI3K Inhibitors, and Novel Targeted Therapies

FEATURING Hayder Saeed
  • 28 views
  • January 27, 2020
21:15

Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Challenging Case of a 55 y/o With Mantle Cell Lymphoma: TP53 Mutations Pose a Considerable Challenge to Conventional Therapy

FEATURING Bijal Shah
  • 322 views
  • January 27, 2020
  • 1
16:35

Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Is CAR T Therapy Now the Preferred 2nd-Line Therapy in Relapsed/Refractory DLBCL: Upcoming Trials May Change the Paradigm

FEATURING Julio Chavez
  • 584 views
  • January 27, 2020
  • 4
20:24

Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Is CAR T Therapy Now the Preferred 2nd-Line Therapy in Relapsed/Refractory DLBCL: Long-term Follow-up Safety Data Is Limited and It Hasn't Been Proven to Be Safer Than ASCT

FEATURING Frederick L. Locke
  • 204 views
  • January 27, 2020